cytarabine has been researched along with vitamin d 2 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Harrison, JS; Studzinski, GP; Wang, X | 2 |
| Danilenko, M; Harrison, JS; Nachliely, M; Studzinski, GP; Wang, X | 1 |
| Danilenko, M; Dawod, A; Harrison, JS; Nachliely, M; Studzinski, GP; Wang, X | 1 |
1 review(s) available for cytarabine and vitamin d 2
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for cytarabine and vitamin d 2
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.
Topics: Abietanes; Annexin A5; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Differentiation; Comet Assay; Cytarabine; DNA Damage; Ergocalciferols; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Propidium; U937 Cells | 2016 |
The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts.
Topics: Abietanes; Adult; Aged; Aged, 80 and over; Apoptosis; Bcl-2-Like Protein 11; Cytarabine; Drug Synergism; Ergocalciferols; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, Calcitriol; RNA Interference; Tumor Cells, Cultured; U937 Cells | 2016 |
Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen.
Topics: Abietanes; Antineoplastic Agents; Antioxidants; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cytarabine; Ergocalciferols; Humans; Leukemia, Myeloid, Acute; MAP Kinase Kinase Kinase 5; Mitogen-Activated Protein Kinase 8; Signal Transduction; Vitamins | 2019 |
Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation.
Topics: Abietanes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antioxidants; Apoptosis; Cell Line, Tumor; Cytarabine; Ergocalciferols; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Reactive Oxygen Species; Receptors, Calcitriol; RNA Interference; RNA, Small Interfering; U937 Cells; Vitamin D | 2020 |